Trial Identifier: | D8220R00038 |
Sponsor: | AstraZeneca |
NCTID:: | NCT05140369 |
Start Date: | October 2021 |
Primary Completion Date: | December 2026 |
Study Completion Date: | December 2026 |
Condition: | CLL (Chronic Lymphocytic Leukemia) |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
No documents have been posted yet.
Country | Location |
---|---|
Russia | Chelyabinsk, Russia |
Russia | Chelyabinsk, Russia |
Russia | Chelyabinsk, Russia |
Russia | Chelyabinsk, Russia |
Russia | Chelyabinsk, Russia |
Russia | Chelyabinsk, Russia |
Russia | Chelyabinsk, Russia |
Russia | Chelyabinsk, Russia |
Russia | Chelyabinsk, Russia |
Russia | Chelyabinsk, Russia |
Russia | Chelyabinsk, Russia |
Russia | Chelyabinsk, Russia |
Russia | Chelyabinsk, Russia |
Russia | Chelyabinsk, Russia |
Russia | Chelyabinsk, Russia |
Russia | Chelyabinsk, Russia |
Russia | Chelyabinsk, Russia |
Russia | Chelyabinsk, Russia |
Russia | Chelyabinsk, Russia |
Russia | Chelyabinsk, Russia |
Russia | Chelyabinsk, Russia |
Russia | Chelyabinsk, Russia |
Russia | Chelyabinsk, Russia |
Russia | Chelyabinsk, Russia |
Russia | Chelyabinsk, Russia |
Russia | Chelyabinsk, Russia |
Russia | Chelyabinsk, Russia |
Russia | Irkutsk, Russia |
Russia | Moscow, Russia |
Russia | Nizhniy Novgorod, Russia |
Russia | Novosibirsk, Russia |
Russia | Saint Petersburg, Russia |